| Métodos para medir la adherencia terapeútica N Pagès-Puigdemont, MI Valverde-Merino Ars Pharmaceutica (Internet) 59 (3), 163-172, 2018 | 364 | 2018 |
| Adherencia terapéutica: factores modificadores y estrategias de mejora MI Valverde-Merino Ars Pharmaceutica (Internet) 59 (4), 251-258, 2018 | 203 | 2018 |
| Patients’ perspective of medication adherence in chronic conditions: a qualitative study N Pages-Puigdemont, MA Mangues, M Masip, G Gabriele, ... Advances in therapy 33, 1740-1754, 2016 | 151 | 2016 |
| Methods to assess medication adherence N Pagès-Puigdemont, M Isabel Valverde-Merino Ars Pharmaceutica 59 (3), 163-172, 2018 | 49 | 2018 |
| Determinants of medication adherence among chronic patients from an urban area: a cross-sectional study N Pages-Puigdemont, L Tuneu, M Masip, P Valls, T Puig, MA Mangues European Journal of Public Health 29 (3), 419-424, 2019 | 25 | 2019 |
| Standard headache and neuralgia treatments and SARS-CoV-2: opinion of the Spanish Society of Neurology’s Headache Study Group N Morollón, R Belvís, A De Dios, N Pagès, C González-Oria, G Latorre, ... Neurología (English Edition) 35 (9), 628-632, 2020 | 16 | 2020 |
| Prevalence and detection of neuropsychiatric adverse effects during hepatitis C treatment M Masip, L Tuneu, N Pagès, X Torras, A Gallego, JM Guardiola, MJ Faus, ... International journal of clinical pharmacy 37, 1143-1151, 2015 | 16 | 2015 |
| A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence D Medina-Catalán, P Riera, N Pagès-Puigdemont, M Masip, ... International Journal of Clinical Pharmacy 44 (3), 725-730, 2022 | 7 | 2022 |
| Medication adherence: modifiers and improvement strategies N Pages-Puigdemont, M Isabel Valverde-Merino Ars Pharmaceutica 59 (4), 251-258, 2018 | 7 | 2018 |
| Potential drug–drug interactions of OMBITASVIR, PARITAPREVIR/ritonavir±DASABUVIR±ribavirin in clinical practice E González‐Colominas, MC Londoño, RM Morillas, X Torras, S Mojal, ... Journal of Gastroenterology and Hepatology 33 (5), 1100-1107, 2018 | 6 | 2018 |
| Abordaje cualitavio y cuantitativo de la adherencia a los tratamientos farmacológicos MA Mangues Bafalluy, L Tuneu Valls Universidad de Granada, 2017 | 5 | 2017 |
| Efectividad del tratamiento de la hepatitis C en pacientes atendidos en la consulta de atención farmacéutica JM Sotoca-Momblona, M Rodriguez-Reyes, C Bartres-Viñas, ... Ars Pharmaceutica (Internet) 61 (1), 45-47, 2020 | 4 | 2020 |
| AB0402 THERAPEUTIC ADHERENCE AND PERSISTENCE OF TOFACITINIB AND BARICITINIB IN RHEUMATOID ARTHRITIS PATIENTS IN DAILY CLINICAL PRACTICE. H Codes-Mendez, C Martinez-Molina, M Masip, P Riera, NP Puigdemont, ... Annals of the Rheumatic Diseases 81 (Suppl 1), 1330-1330, 2022 | 3 | 2022 |
| ¿ Cuál es el beneficio del uso de las estatinas en el anciano CM Cantera, S Creu, S Pau, JT Borrell Butlletí d’Informació Terapèutica 25 (6), 2014 | 3 | 2014 |
| Tratamientos habituales utilizados en cefaleas, neuralgias y SARS-CoV-2. Posicionamiento del grupo de estudio de cefaleas de la Sociedad Española de Neurología N Morollón, R Belvís, A De Dios, N Pagès, C González-Oria, G Latorre, ... Neurología 35 (9), 628-632, 2020 | 2 | 2020 |
| Design of a relative value unit-based tool for the measurement and reimbursement of pharmacy services for clinical trials N Pagès-Puigdemont, G Molas, MQ Gorgas, N Berga, C Codina, M Cruel, ... European Journal of Hospital Pharmacy 26 (4), 205-209, 2019 | 2 | 2019 |
| 4CPS-251 Impact of a multidisciplinary team in reducing polypharmacy and treatment complexity in home care patients N Pagès-Puigdemont, M Rovira-Illamola, L Gené, I Garrell, L GUerrero, ... European Journal of Hospital Pharmacy 26 (Suppl 1), A186-A186, 2019 | 2 | 2019 |
| What if a monoclonal antibody doesn't work as a migraine preventive treatment? Description of the experience in switching between monoclonals antibodies in a Headache Unit N Morollon, R Belvis, A De Dios, N Pages, M Massip JOURNAL OF HEADACHE AND PAIN 22 (SUPPL 1), 106-106, 2021 | 1 | 2021 |
| Changes in antiretroviral treatment due to interactions in co-infected patients who initiate treatment for chronic hepatitis C virus M Saavedra Mitjans, N Pages Puigdemont, N Garin Escriva, ... INTERNATIONAL JOURNAL OF CLINICAL PHARMACY 39 (1), 214-215, 2017 | 1 | 2017 |
| Treatment with Sofosbuvir+ Simeprevir for 12 Weeks in HCV Compensated Cirrhosis (Genotypes 1 and 4); The Use of Ribavirin Does Not Influence Sustained Viral Response A Gallego, E Alvarado, C Gely, N Pagès, M Masip, N Margall, X Torras, ... Journal of Hepatology 2 (64), S741-S742, 2016 | 1 | 2016 |
